Evaluation of the meritas® BNP test for point-of-care testing

Clinical Laboratory

Volumn 61, Issue 7, 2015, Pages 727-730

  Olausson, Johan ^a   Petersonl, Christer ^a,b   Bergstrom, Mats ^c   Larsson, Anders ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b Fiomi Diagnostics AB   (Sweden)

^c Unilabs   (France)

Author keywords

Method evaluation; NT proBNP; Point of care test; Primary care

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; IMMOBILIZED ANTIBODY; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ANALYZER; ARTICLE; ASSAY; BRAIN NATRIURETIC PEPTIDE ASSAY; CONTROLLED STUDY; HEART FAILURE; HUMAN; IMMUNOASSAY ANALYZER; MAJOR CLINICAL STUDY; MERITAS BRAIN NATRIURETIC PEPTIDE ANALYZER; POINT OF CARE TESTING; PRIMARY MEDICAL CARE; BLOOD; COMPARATIVE STUDY; DEVICES; EQUIPMENT DESIGN; EVALUATION STUDY; HOSPITAL INFORMATION SYSTEM; IMMUNOASSAY; PREDICTIVE VALUE; TIME;

BIOLOGICAL MARKERS; EQUIPMENT DESIGN; HEART FAILURE; HUMANS; IMMUNOASSAY; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; TIME FACTORS;

EID: 84938684505     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2014.140815     Document Type: Article

References (13)

1. Jhund PS, Macintyre K, Simpson CR, et al. Long-term trends in first hospitalization for heart failure and subsequent survival between 1986 and 2003: A population study of 5.1 million people. Circulation 2009;119:515-23.
2. Stewart S, Ekman I, Ekman T, Oden A, Rosengren A. Population impact of heart failure and the most common forms of cancer: A study of 1 162 309 hospital cases in Sweden 1988 to 2004. Circ Cardiovasc Qual Outcomes 2010;3:573-80.
3. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012;33:1787-847.
4. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006;11:95-107.
5. Kelder JC, Cramer MJ, van Wijngaarden J, et al. The diagnostic value of physical examination and additional testing in primary care patients with suspected heart failure. Circulation 2011; 124: 2865-73.
6. Marwick TH, Raman SV, Carrio I, Bax JJ. Recent developments in heart failure imaging. JACC Cardiovasc Imaging 2010;3:429-39.
7. Paterson DI, OMeara E, Chow BJ, Ukkonen H, Beanlands RS. Recent advances in cardiac imaging for patients with heart failure. Curr Opin Cardiol 2011;26:132-43.
8. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10:824-39.
9. Ferrandis MJ, Ryden I, Lindahl TL, Larsson A. Ruling out cardiac failure: Cost-benefit analysis of a sequential testing strategy with NT-proBNP before echocardiography. Ups J Med Sci 2013; 118:75-9.
10. Seyyed Khezri B, Helmersson-Karlqvist J, Larsson A. Estimation of the possible economic effects of a sequential testing strategy with NT-proBNP before echocardiography in primaiy care. Clinical Laboratory 2014;60:881-6.
11. Tamm NN, Seferian KR, Semenov AG, et al. Novel immunoassay for quantification of brain natriuretic peptide and its precursor in human blood. Clinical Chemistry 2008;54:1511-8.
12. Barents M, van der Horst I, Voors A, Hillege J, Muskiet FA, de Jongste MJ. Prevalence and misdiagnosis of chronic heart failure in nursing home residents: The role of B-type natriuretic peptides. Netherlands Heart Journal 2008;16:123-8.
13. Davies M, Hobbs F, Davis R, et al. Prevalence of left ventricular systolic dysfunction and heart failure in the Echocardiographic Heart of England Screening study: A population based study. Lancet 2001;358:439-44.